Business
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n REHOVOT, Israel, SINGAPORE and NEW YORK, NY, Aug. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has appointed Jorge Leon, Ph.D. as consulting Chief Medical and Scientific Officer (CMSO) for Infectious Disease and Oncology. Dr. Leon has served as Todos’ medical advisor since July 2019. “As medical advisor I have been able to follow Todos’ progress over the last year as they’ve continued to build their exciting pipeline of diagnostics for cancer and Alzheimer’s disease,” said Dr. Leon. “The approach Todos has taken to enter COVID-19 testing has been spot on, by focusing on an accurate, scalable and diverse product portfolio, coupled with reliable access to the key instrumentation needed to equip a large number of labs and supply them with the reagents and consumables needed to make a meaningful increase to PCR testing capacity in the United States. “As we now have a clear framework from the U.S. Food and Drug Administration (FDA) to gain Emergency Use Authorization (EUA) for COVID+influenza A/B and COVID pool testing, we believe we are entering the fall with the right portfolio to become a significant player in the space,” he added. “We intend to begin to establish combined screening and reflex testing strategies using antigen, antibody and PCR pooling testing to screen patients and ultimately confirm the suspected COVID-19 cases with PCR testing. Todos is also developing an innovative saliva-based molecular test that could deliver point-of-care results in under five minutes, using a smartphone camera and software, which would represent a major advancement for the field. We expect to initiate clinical validation of that test in August in Israel with the hopes of gathering sufficient data to submit an EUA.” Dr. Leon is internationally recognized for his pioneering work in molecular diagnostics. He holds a Ph.D. in cellular and molecular biology from New York University, and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and Columbia University in Ne...